Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged strategy to address neurological health, focusing on both a potential multiple sclerosis (MS) therapy and a dietary supplement aimed at mitigating the effects of alcohol. This dual approach underscores the company’s commitment to tackling complex conditions through different mechanisms, potentially broadening its impact on public health.
The first prong is Lucid-MS, an investigational therapy designed to target PAD2, an enzyme associated with myelin degradation. Unlike conventional MS treatments that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath, the protective covering of nerve fibers that is damaged in MS. This novel mechanism could represent a significant shift in how MS is treated, offering hope for disease modification rather than just symptom management. The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial, and is supporting development through an imaging collaboration with Massachusetts General Hospital. This partnership could provide critical insights into the drug’s efficacy by tracking myelin changes in patients.
The second prong is unbuzzd, a proprietary dietary supplement designed to support alcohol metabolism and reduce acute intoxication and hangover effects. Quantum BioPharma has cited results from a randomized, placebo-controlled clinical trial supporting its claims. Unbuzzd was invented by Quantum BioPharma and spun out to Unbuzzd Wellness Inc. (UWI), with Quantum retaining a 19.84% ownership stake as of March 31, 2026. The agreement also includes royalty payments: 7% of sales until Quantum receives $250 million, after which the royalty drops to 3% in perpetuity. Importantly, Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses, positioning it to leverage unbuzzd’s active ingredients in future therapeutic applications.
The importance of this dual strategy lies in its potential to address two significant public health challenges. MS is a chronic, often disabling disease that affects millions worldwide, and current treatments are not curative. If Lucid-MS proves effective in clinical trials, it could offer a new approach that directly targets the underlying cause of myelin damage. On the other hand, alcohol misuse and its associated health consequences, including hangovers and long-term organ damage, are widespread. A supplement that can safely reduce intoxication and hangover severity could have broad consumer appeal and also serve as a foundation for future pharmaceutical interventions for alcohol misuse disorders.
Quantum BioPharma’s pipeline also includes drug candidates for neurodegenerative and metabolic disorders, reflecting a broader mission to innovate in areas of high unmet need. The company’s focus on both a regulated therapeutic and a consumer product demonstrates a strategic balance between high-risk, high-reward drug development and more immediate market opportunities. The success of unbuzzd could generate revenue to support the costly development of Lucid-MS, creating a symbiotic relationship between the two initiatives.
As Quantum BioPharma advances these programs, the outcomes will be closely watched by investors and the medical community. The FDA’s response to the IND application for Lucid-MS will be a key milestone, and the commercial performance of unbuzzd will provide insights into its acceptance among consumers. For more information, visit the company’s newsroom at https://ibn.fm/QNTM.
